Vasily M. Gelfanov
Novo Nordisk (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Chemical Synthesis and Analysis, Receptor Mechanisms and Signaling, Neuropeptides and Animal Physiology
Most-Cited Works
- → Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans(2013)661 cited
- → A new glucagon and GLP-1 co-agonist eliminates obesity in rodents(2009)624 cited
- → A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents(2014)614 cited
- → Targeted estrogen delivery reverses the metabolic syndrome(2012)322 cited
- → Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide(2000)294 cited
- → Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions(2013)241 cited
- → Unimolecular Polypharmacy for Treatment of Diabetes and Obesity(2016)227 cited
- → Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism(2018)218 cited
- → Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease(2016)188 cited
- → Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents(2012)134 cited